Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Intern Med. 1998 Dec 15;129(12):1027-30.

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.

Author information

  • 1Hamamatsu University School of Medicine and Honda Motor Co., Ltd., Japan. furuta@akiha.hama-med.ac.jp

Abstract

BACKGROUND:

Omeprazole is metabolized by S-mephenytoin 4'-hydroxylase (CYP2C19) in the liver. In persons with a poor-metabolizer genotype for CYP2C19, the therapeutic efficacy of omeprazole may be increased.

OBJECTIVE:

To investigate whether CYP2C19 genotype status is associated with cure rates for Helicobacterpylori infection and peptic ulcer achieved by using dual therapy with omeprazole and amoxicillin.

DESIGN:

Prospective cohort study.

SETTING:

University hospital and health service center in Hamamatsu, Japan.

PATIENTS:

62 patients with peptic ulcer and H. pylori infection.

INTERVENTION:

Omeprazole and amoxicillin.

MEASUREMENTS:

CYP2C19 genotype status and cure rates for H. pylori infection and peptic ulcer.

RESULTS:

Cure rates for H. pylori infection were 28.6% (95% CI, 13.1% to 48.7%), 60% (CI, 38.6% to 83.0%), and 100% (CI, 66.4% to 100%) in the rapid-, intermediate-, and poor-metabolizer groups, respectively. Healing rates for both duodenal and gastric ulcer in the three groups were roughly parallel with cure rates for H. pylori infection.

CONCLUSION:

The results of the genotyping test for CYP2C19 seem to predict cure of H. pylori infection and peptic ulcer in patients who receive dual therapy with omeprazole and amoxicillin.

PMID:
9867757
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center